FDA approves intratumoral injection for nonmetastatic mast cell tumors in dogs
The Food and Drug Administration announced Nov. 16, 2020, that the agency granted approval of Stelfonta, or tigilanol tiglate injection, to QBiotics Group Ltd. for the treatment of dogs with nonmetastatic, cutaneous mast cell tumors. The FDA also approved Stelfonta to treat nonmetastatic, subcutaneous MCTs located in particular areas of a dog’s leg.
Stelfonta is injected directly into the MCT and works by activating a protein that spreads throughout the treated tumor, disintegrating tumor cells.
MCTs are the most common malignant skin tumor in dogs. Full surgical removal of MCTs can be difficult when tumors are located in certain areas, such as the leg. When MCTs are not fully removed, the remaining malignant cells can start to grow and spread rapidly. Stelfonta offers a novel way to treat nonmetastatic MCTs as the only approved intratumoral injection.
The label for Stelfonta carries a warning for human safety because of the risk of severe wound formation from accidental self-injection or needle stick injuries. The warning also includes statements regarding the safe use of Stelfonta in dogs. Stelfonta should always be given with a corticosteroid, an H1 receptor blocking agent, and an H2 receptor blocking agent to decrease the risk of severe systemic adverse reactions, including death, from mast cell degranulation. Veterinarians should provide the client information sheet to pet owners for information about Stelfonta and how to care for pets after they have been given the drug.
New Jersey students can apply for scholarship
The American Veterinary Medical Foundation, in partnership with the Harold Wetterberg Foundation, is once again awarding scholarships to current or former residents of New Jersey who are pursuing a career in veterinary medicine.
Applicants must be second- or third-year veterinary students or students enrolled in postgraduate education in veterinary medicine, have graduated from a New Jersey high school, and have had a 3.0 GPA or higher at their veterinary school and undergraduate school. Preference is given to students pursuing dual degrees and those who have graduated from or attended a university in New Jersey.
Award amounts range from $5,000-$15,000 to the winners; previous recipients are eligible to apply. The deadline for this scholarship program is March 15.
For additional details, contact Patti Gillespie, AVMF senior manager of programs and operations, at pgillespie
avma [dot] org or 847-285-6709.
Winn announces almost $165,000 in grants for feline health studies
In November 2020, the Winn Feline Foundation announced $164,499 in funding, in partnership with the George Sydney and Phyllis Redman Miller Trust, for the following six feline health studies:
- “Impact of iron deficiency on short-term T-cell response to treatment in cats with inflammatory bowel disease.”
- “Characterization of myeloid cell phenotypes and frequencies in feline cancers and infectious disease.”
- “Effects of dual antithrombotic therapy using rivaroxaban and clopidrogrel on platelet function and coagulation parameters in cats.”
- “Development of improved cell culture systems for feline coronavirus and FIP vaccine development, Aim 2.”
- “Feline congenital primary hypothyroidism: Establishing normal reference intervals and treatment guidelines.”
- “High density cat DNA array genome-wide association studies.”
Please send comments and story ideas to JAVMANewsavma [dot] org.
"Short" - Google News
January 07, 2021 at 01:07AM
https://ift.tt/38knuKM
In Short - American Veterinary Medical Association
"Short" - Google News
https://ift.tt/2QJPxcA
Bagikan Berita Ini
0 Response to "In Short - American Veterinary Medical Association"
Post a Comment